Sanara MedTech Q4 2024 Earnings Report
Key Takeaways
Sanara MedTech achieved net revenue of $26.3 million in Q4 2024, representing a 49% increase compared to the prior year. Gross profit rose to $24.1 million with a strong margin of 91%. Despite these gains, the company recorded a net loss of $1.7 million, influenced by higher SG&A and R&D costs, as well as increased interest expenses.
Q4 2024 net revenue rose 49% year-over-year to $26.3 million.
Gross profit reached $24.1 million, with a 91% gross margin.
Net loss widened to $1.7 million, impacted by increased SG&A, R&D, and interest expenses.
Soft tissue repair products sales increased 56%, driving overall revenue growth.
Sanara MedTech
Sanara MedTech
Sanara MedTech Revenue by Segment
Forward Guidance
Sanara MedTech plans to continue investing in its Tissue Health Plus platform in 2025, with a pilot program launch expected in Q2, while focusing on profitability improvements in the Sanara Surgical segment.
Positive Outlook
- Continued investment in Tissue Health Plus platform development.
- Planned pilot launch of Tissue Health Plus with a wound care provider group in Q2 2025.
- Focus on expanding sales and product penetration.
- Ongoing R&D to enhance antimicrobial technologies and collagen-based products.
- Pursuit of financial partnerships to support strategic initiatives.
Challenges Ahead
- Expected increased SG&A and R&D expenses related to new platform buildout.
- Interest expenses remain elevated due to term loan obligations.
- Higher depreciation from software asset write-offs.
- Continued net losses expected in the short term from Tissue Health Plus investments.
- Uncertainty in supply chain conditions may impact sales growth stability.
Revenue & Expenses
Visualization of income flow from segment revenue to net income